Literature DB >> 15683515

Expression of opioid receptor subtypes and their ligands in fibrillating human atria.

Uwe Lendeckel1, Cornelia Müller, Christoph Röcken, Britta Laube, Michael Täger, Christof Huth, Helmut U Klein, Andreas Goette.   

Abstract

The delta- and kappa-receptor subtypes are both abundantly expressed in the human heart and participate in age- and stress-related alterations of cardiac function. Opioid receptor agonists mediate cardioprotection in response to ischemic preconditioning via increased intracellular Ca(2) (+) levels, opening mitochondrial K(ATP) channels, and PKC activation. We studied the expression of opioid receptor subtypes kappa and delta, and of their ligand precursors, proopiomelanocortin (POMC) and preproenkephalin A (PENKA), in human atrial tissue of patients in sinus rhythm (SR), or persistent atrial fibrillation (AF). The mitochondrial size was also compared between the two groups. The atrial mRNA expression of opioid peptide precursors and receptors was assessed by competitive and real-time RT-PCR in 16 patients in AF and 16 patients in SR. Mitochondria were analyzed in the atrial tissue by electron microscopy in four patients in AF and four patients in SR. Both PENKA (SR: 100 +/- 33% vs AF: 33 +/- 21%; P < 0.05) and kappa-receptor mRNA amounts (AF: 78 +/- 20% vs SR: 100 +/- 11%; P < 0.05) were both decreased in AF in comparison to SR. In addition, POMC mRNA levels were decreased in AF (SR: 100 +/- 54% vs AF: 37 +/- 26%; P < 0.05), whereas the expression of the corresponding delta-opioid receptor was unchanged (AF: 102 +/- 34% vs 100 +/- 44%). Mitochondrial size was increased during persistent AF. Persistent AF is associated with the down-regulation of the opioid receptor/ligand expression. This suggests a loss of protective capacity in the fibrillating atrial tissue, resulting in an ultrastructural remodeling of atrial myocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683515     DOI: 10.1111/j.1540-8159.2005.00073.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

Review 1.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue.

Authors:  Piotr Sobanski; Malgorzata Krajnik; Mohammed Shaqura; Elzbieta Bloch-Boguslawska; Michael Schäfer; Shaaban A Mousa
Journal:  Heart Vessels       Date:  2014-01-05       Impact factor: 2.037

Review 3.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  Evidence for MOR on cell membrane, sarcoplasmatic reticulum and mitochondria in left ventricular myocardium in rats.

Authors:  Sascha Treskatsch; Mohammed Shaqura; Lukas Dehe; Torsten K Roepke; Mehdi Shakibaei; Michael Schäfer; Shaaban A Mousa
Journal:  Heart Vessels       Date:  2015-12-19       Impact factor: 2.037

5.  Association Between Opioid Use and Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Waqas T Qureshi; Wesley T O'Neal; Yulia Khodneva; Suzanne Judd; Monika M Safford; Paul Muntner; Elsayed Z Soliman
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

Review 6.  Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal.

Authors:  Olurotimi O Mesubi; Mark E Anderson
Journal:  Cardiovasc Res       Date:  2016-01-13       Impact factor: 10.787

7.  Mitochondrial oxidative stress promotes atrial fibrillation.

Authors:  Wenjun Xie; Gaetano Santulli; Steven R Reiken; Qi Yuan; Brent W Osborne; Bi-Xing Chen; Andrew R Marks
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

8.  Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study.

Authors:  Cynthia Wei-Sheng Lee; Chih-Hsin Muo; Ji-An Liang; Ming-Chia Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.

Authors:  Jeffrey J Buda; F I Carroll; Thomas R Kosten; Dennis Swearingen; Bradford B Walters
Journal:  Neuropsychopharmacology       Date:  2015-01-23       Impact factor: 7.853

10.  Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors.

Authors:  Peter Boknik; Katharina Drzewiecki; John Eskandar; Ulrich Gergs; Britt Hofmann; Hendrik Treede; Stephanie Grote-Wessels; Larissa Fabritz; Paulus Kirchhof; Lisa Fortmüller; Frank Ulrich Müller; Wilhelm Schmitz; Norbert Zimmermann; Uwe Kirchhefer; Joachim Neumann
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.